Popular
LKFT · Medicine & biotech · Belgium

Lakefront Biotherapeutics

Formerly Galapagos; develops drugs for immune system diseases.

Company Health

60
/100
Mixed
A quick check of the business from its yearly reports (2022–2025). It doesn’t say whether the stock is a good buy.
Does it make money?
25 of 25 · Good
€29 of every €100 in sales was left as profit last year.
Is it growing?
25 of 25 · Good
Sales grew about 66% a year over the last 3 years.
Can it handle what it owes?
10 of 25 · Okay
Its business used cash last year, and it owes €5 of every €100 it owns.
Does it bring in spare cash?
0 of 25 · Poor
It spent more cash than it brought in: €24 of every €100 in sales.

Who owns it

1 of 23 own it · Nobody changed their stake
bought lately
owns it
doesn’t own it
Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Duquesne, Himalaya Capital, Giverny Capital, Fundsmith, Semper Augustus, Akre
Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners
From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Lakefront Biotherapeutics’ yearly reports, in euros. Tap a year to see its figures.

Sales and profit

Sales grew from €478 million in 2020 to €1.11 billion in 2025, and it made a profit in 3 of the 6 years.
2025
Sales
€1.11 billion
Profit
€321 million

Spare cash each year

It spent more cash than it brought in every year: €271 million more in 2025.
2025
Cash shortfall
€271 million
Spare cash is the cash its business brought in, minus what it spent on buildings and equipment.

What it owns and what it owes

At the end of 2025 it owned €3.41 billion, including €87.9 million in cash, and owed €171 million.

Key facts

From its yearly report for 2025.
Sales
€1.11 billion
Profit
€321 million
Cash shortfall
€271 million
Cash in the bank
€87.9 million
Everything it owes
€171 million
Year ends
December
Money shown in
Euros
Latest yearly report
20-F, filed Mar 26, 2026
Figures from Lakefront Biotherapeutics’ yearly reports to the SEC (EDGAR), collected Oct 12, 2026.
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works
Privacy policy